Cargando…
Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study
BACKGROUND AND AIMS: Quetiapine is an atypical antipsychotic predominantly metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. We studied the risk of adverse events following coprescription of clarithromycin (a strong CYP3A4 inhibitor) versus azithromycin (not a CYP3A4 inhibitor) in quetiapine u...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290079/ https://www.ncbi.nlm.nih.gov/pubmed/37359413 http://dx.doi.org/10.1002/hsr2.1375 |
_version_ | 1785062414320926720 |
---|---|
author | Yau, Kevin McArthur, Eric Jeyakumar, Nivethika Tsobo Muanda, Flory Kim, Richard B. Clemens, Kristin K. Wald, Ron Garg, Amit X. |
author_facet | Yau, Kevin McArthur, Eric Jeyakumar, Nivethika Tsobo Muanda, Flory Kim, Richard B. Clemens, Kristin K. Wald, Ron Garg, Amit X. |
author_sort | Yau, Kevin |
collection | PubMed |
description | BACKGROUND AND AIMS: Quetiapine is an atypical antipsychotic predominantly metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. We studied the risk of adverse events following coprescription of clarithromycin (a strong CYP3A4 inhibitor) versus azithromycin (not a CYP3A4 inhibitor) in quetiapine users. MATERIALS AND METHODS: This was a population‐based retrospective cohort study from 2004 to 2020 in Ontario, Canada in adult quetiapine users newly co‐prescribed clarithromycin (n = 16,909) or azithromycin (n = 25,267). The primary outcome was the composite of hospital encounters with encephalopathy (defined as a diagnosis of delirium, disorientation, transient alteration of awareness, transient ischemic attack, or unspecified dementia), a fall, or a fracture within 30 days of new coprescription. Secondary outcomes were individual components of the composite outcome, hospital encounter with computed tomography (CT) head scan, and all‐cause mortality. RESULTS: Coprescription of clarithromycin versus azithromycin with quetiapine was associated with a higher risk of the primary composite outcome (365 of 16,909 clarithromycin users [2.2%] vs. 309 of 16,929 azithromycin users [1.8%]; absolute risk increase, 0.34% [95% confidence interval, CI, 0.04–0.63]; relative risk [RR], 1.19 [95% CI, 1.02–1.38]). This was primarily driven by an increase in fragility fractures (78 of 16,909 clarithromycin users [0.5%] vs. 45 of 16,923 azithromycin users [0.3%]; absolute risk increase, 0.20% [95% CI, 0.07–0.32]; RR, 1.74 [95% CI, 1.21–2.52]). Hospital encounters with a CT head scan were higher in clarithromycin users (220 of 16,909 [1.3%] vs. 175 of 16,923 azithromycin users [1.0%]; absolute risk increase, 0.27% [95% CI, 0.04–0.50]; RR, 1.26 [95% CI, 1.04–1.54]), but there was no difference in hospital encounters with encephalopathy, falls, or all‐cause mortality between macrolide groups. CONCLUSION: Among adults taking quetiapine, concurrent use of clarithromycin compared with azithromycin was associated with a small but statistically greater 30‐day risk of a hospital encounter for encephalopathy, falls, or fracture, which was predominantly related to a higher rate of fragility fractures. |
format | Online Article Text |
id | pubmed-10290079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102900792023-06-25 Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study Yau, Kevin McArthur, Eric Jeyakumar, Nivethika Tsobo Muanda, Flory Kim, Richard B. Clemens, Kristin K. Wald, Ron Garg, Amit X. Health Sci Rep Original Research BACKGROUND AND AIMS: Quetiapine is an atypical antipsychotic predominantly metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. We studied the risk of adverse events following coprescription of clarithromycin (a strong CYP3A4 inhibitor) versus azithromycin (not a CYP3A4 inhibitor) in quetiapine users. MATERIALS AND METHODS: This was a population‐based retrospective cohort study from 2004 to 2020 in Ontario, Canada in adult quetiapine users newly co‐prescribed clarithromycin (n = 16,909) or azithromycin (n = 25,267). The primary outcome was the composite of hospital encounters with encephalopathy (defined as a diagnosis of delirium, disorientation, transient alteration of awareness, transient ischemic attack, or unspecified dementia), a fall, or a fracture within 30 days of new coprescription. Secondary outcomes were individual components of the composite outcome, hospital encounter with computed tomography (CT) head scan, and all‐cause mortality. RESULTS: Coprescription of clarithromycin versus azithromycin with quetiapine was associated with a higher risk of the primary composite outcome (365 of 16,909 clarithromycin users [2.2%] vs. 309 of 16,929 azithromycin users [1.8%]; absolute risk increase, 0.34% [95% confidence interval, CI, 0.04–0.63]; relative risk [RR], 1.19 [95% CI, 1.02–1.38]). This was primarily driven by an increase in fragility fractures (78 of 16,909 clarithromycin users [0.5%] vs. 45 of 16,923 azithromycin users [0.3%]; absolute risk increase, 0.20% [95% CI, 0.07–0.32]; RR, 1.74 [95% CI, 1.21–2.52]). Hospital encounters with a CT head scan were higher in clarithromycin users (220 of 16,909 [1.3%] vs. 175 of 16,923 azithromycin users [1.0%]; absolute risk increase, 0.27% [95% CI, 0.04–0.50]; RR, 1.26 [95% CI, 1.04–1.54]), but there was no difference in hospital encounters with encephalopathy, falls, or all‐cause mortality between macrolide groups. CONCLUSION: Among adults taking quetiapine, concurrent use of clarithromycin compared with azithromycin was associated with a small but statistically greater 30‐day risk of a hospital encounter for encephalopathy, falls, or fracture, which was predominantly related to a higher rate of fragility fractures. John Wiley and Sons Inc. 2023-06-23 /pmc/articles/PMC10290079/ /pubmed/37359413 http://dx.doi.org/10.1002/hsr2.1375 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Yau, Kevin McArthur, Eric Jeyakumar, Nivethika Tsobo Muanda, Flory Kim, Richard B. Clemens, Kristin K. Wald, Ron Garg, Amit X. Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study |
title | Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study |
title_full | Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study |
title_fullStr | Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study |
title_full_unstemmed | Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study |
title_short | Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study |
title_sort | adverse events with quetiapine and clarithromycin coprescription: a population‐based retrospective cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290079/ https://www.ncbi.nlm.nih.gov/pubmed/37359413 http://dx.doi.org/10.1002/hsr2.1375 |
work_keys_str_mv | AT yaukevin adverseeventswithquetiapineandclarithromycincoprescriptionapopulationbasedretrospectivecohortstudy AT mcarthureric adverseeventswithquetiapineandclarithromycincoprescriptionapopulationbasedretrospectivecohortstudy AT jeyakumarnivethika adverseeventswithquetiapineandclarithromycincoprescriptionapopulationbasedretrospectivecohortstudy AT tsobomuandaflory adverseeventswithquetiapineandclarithromycincoprescriptionapopulationbasedretrospectivecohortstudy AT kimrichardb adverseeventswithquetiapineandclarithromycincoprescriptionapopulationbasedretrospectivecohortstudy AT clemenskristink adverseeventswithquetiapineandclarithromycincoprescriptionapopulationbasedretrospectivecohortstudy AT waldron adverseeventswithquetiapineandclarithromycincoprescriptionapopulationbasedretrospectivecohortstudy AT gargamitx adverseeventswithquetiapineandclarithromycincoprescriptionapopulationbasedretrospectivecohortstudy |